Valeant adds shareholder John Paulson to board

Ivan Schwartz
June 19, 2017

Its down 0.10, from 0.88 in 2016Q3. Valeant Pharmaceuticals Intl Inc (NYSE:VRX)'s total market worth is $4.53B along with 341.19M outstanding shares.

Other hedge funds have also recently added to or reduced their stakes in the company. Royal Bank Of Canada reduced their target price on shares of Valeant Pharmaceuticals International to $21.00 in a report on Wednesday, March 1st. 14,674,829 shares of the stock traded hands. Jpmorgan Chase Com stated it has 0% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Armstrong Henry H Associate Inc reported 93,748 shares stake. Stanley Mngmt Lc owns 155,300 shares. Pension Serv reported 0.03% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Marathon Trading Invest Mgmt Ltd Liability Corp accumulated 0.09% or 56,098 shares. 484,618 are owned by Cibc Asset Mngmt Incorporated. Dimensional Fund Advisors L P, a Texas-based fund reported 576,634 shares. Continental Advsrs Ltd Co reported 117,300 shares. The specialty pharmaceutical company reported $2.80 EPS for the quarter, topping the Zacks' consensus estimate of $0.87 by $1.93. Illinois-based Peak6 Investments Limited Partnership has invested 0.01% in Valeant Pharmaceuticals Intl Inc (TSE:VRX). Citigroup Inc holds 137,268 shares or 0% of its portfolio. Tiaa Cref Limited Liability Corporation owns 0.01% invested in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 479,756 shares.

Since March 13, 2017, it had 3 insider purchases, and 1 insider sale for $166.26 million activity. ValueAct Holdings - L.P. also bought $32.47M worth of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares.

London police plead for calm after attack at mosque
Witnesses described hearing the man, who was detained by members of the public at the scene, shout: "I'm going to kill Muslims". He's "been taken to hospital as a precaution", where he'll receive a mental health assessment , according to the statement.

One dead as van rams pedestrians near London mosque
UK Prime Minister Theresa May also called the incident a terror attack when she addressed reporters outside Downing Street Monday. Muslims pray on a sidewalk in the Finsbury Park area of north London after a vehicle hit pedestrians, on June 19, 2017 .

Vegas holds all the cards with NHL expansion draft list out
The Golden Knights have agreed to not take those players. "Every team in this league has a chance to protect their roster". No matter what strategy the Golden Knights use in the expansion draft, they're going to find the guys they want.

In other Valeant Pharmaceuticals International news, Director Schutter Richard U. De acquired 20,000 shares of the stock in a transaction that occurred on Thursday, May 11th. In a transaction dated March 14, 2017, the shares were bought at an average price of $10.72, giving away a sum of $257,280. On Monday, March 13 the insider Pershing Square Capital Management - L.P. sold $199.26 million.

Cantor Fitzgerald analyst initiated coverage on Valeant Pharmaceuticals International VRX (NYSE:VRX) with a $18.00 PT and "Overweight" rating. The TP is exactly $18.00. Guggenheim restated a "buy" rating and issued a $55.00 price target on shares of Valeant Pharmaceuticals International in a research report on Tuesday, February 28th. Therefore 24% are positive. Valeant Pharmaceuticals International, Inc. has a 1-year low of $8.31 and a 1-year high of $32.74. $72.29's average target is 471.01% above currents $12.66 stock price. On average, analysts predict that Valeant Pharmaceuticals International, Inc. will post $3.89 EPS for the current year. On Wednesday, October 14 the stock rating was maintained by Scotia Capital with "Sector Outperform". The firm has "Market Perform" rating by BMO Capital Markets given on Wednesday, June 29. The stock has "Outperform" rating by RBC Capital Markets on Monday, December 14. RBC Capital Markets maintained Valeant Pharmaceuticals Intl Inc (NYSE:VRX) rating on Friday, May 5.

Among 4 analysts covering Lundin Gold (TSE:LUG), 4 have Buy rating, 0 Sell and 0 Hold. The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) earned "Buy" rating by Bank of America on Wednesday, September 30. RBC Capital Markets maintained Valeant Pharmaceuticals Intl Inc (NYSE:VRX) rating on Tuesday, October 27. The firm has made a decision to set a Overweight rating along with a $18.00, adding 42.18 % to the target. The stock was last seen 4.46% higher, reaching at $12.66 on June 16, 2017. It has underperformed by 65.21% the S&P500. Paulson & Co. Inc. owns $245.41 million in Valeant Pharmaceuticals International, Inc., which represents roughly 5.54% of the company's market cap and approximately 10.87% of the institutional ownership. The stock's market capitalization is $4.22 billion. The Company is involved in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in over 100 countries. It now has negative earnings. The Company operates through two segments: Developed markets and Emerging markets.

Other reports by GizPress

Discuss This Article